Tech Company Financing Transactions
Sen-Jam Pharmaceutical Funding Round
Sen-Jam Pharmaceutical closed a financing round on 1/22/2025. Investors included 5 Horizons Capital.
Transaction Overview
Company Name
Announced On
1/22/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to delivering scalable and accessible solutions that enhance global health outcomes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
New York, NY Undisclosed
USA
New York, NY Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Sen-Jam Pharmaceutical is focused on improving clinical outcomes for patients battling inflammation-based diseases such as viral respiratory infections from coronaviruses such as COVID-19 and other painful inflammation and toxin-induced conditions, including arthritis, vaccinations, opioid withdrawal and even the infamous hangover. Using our patented proprietary technology of "next generation anti-inflammatories" and the accelerated 505(b)2 pathway, we're addressing the root causes of autoimmune inflammation--much like how Ozempic targets metabolic inflammation.. Our mission: to transform how we treat inflammation and reshape the business of pain relief for the betterment of humanity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jim Iversen
Browse more venture capital transactions:
Prev: 1/22/2025: Databricks venture capital transaction
Next: 1/22/2025: Teal venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs